Agent that triggers immune response in plants is uncoveredOctober 05, 2007Although plants lack humans' T cells and other immune-function cells to signal and fight infection, scientists have known for more than 100 years that plants still somehow signal that they have been attacked in order to trigger a plantwide resistance. Now, researchers at the Boyce Thompson Institute for Plant Research (BTI) on the Cornell campus have identified the elusive signal in the process: methyl salicylate, an aspirin-like compound that alerts a plant's immune system to shift into high gear. This phenomenon is called systemic acquired resistance and is known to require movement of a signal from the site of infection to uninfected parts of the plant. The findings are published in the Oct. 5 issue of Science. "By finally identifying a signal that moves from an infection site to activate defenses throughout the plant, as well as the enzymes that regulate the level of this signal, we may be in a position to alter the signal in a way that enhances a plant's ability to defend itself," said BTI senior scientist Daniel F. Klessig, an adjunct professor in plant pathology at Cornell, who conducted the work with Sang-Wook Park and other BTI colleagues. Their approach, using gene technology to enhance plant immunity, could have wide consequences, boosting crop production and reducing pesticide use. Methyl salicylate is a modified form of salicylic acid (SA), which has been used for centuries to relieve fever, pain and inflammation, first through the use of willow bark and, since 1889, with aspirin, still the most widely used drug worldwide. In the 1990s, Klessig's research group reported that SA and nitric oxide are two critical defense-signaling molecules in plants, as well as playing important roles in human health. Then, in 2003 and 2005, the group reported in the Proceedings of the National Academy of Sciences that an enzyme, salicylic acid-binding protein 2 (SABP2), is required for systemic acquired resistance and converts methyl salicylate (which is biologically inactive as it fails to induce immune responses) into SA, which is biologically active. After plants are attacked by a pathogen, the researchers had previously found, they produce SA at the infection site to activate their defenses. Some of the SA is converted into methyl salicylate, which can be converted back into SA by SABP2. Using plants in which SABP2 function was either normal, turned off or mutated in the infected leaves or the upper, uninfected leaves, Klessig's group showed that SABP2 must be active in the upper, uninfected leaves for systemic acquired resistance to develop properly. By contrast, SABP2 must be inactivated in the infected leaves by binding to SA. "This inactivation allows methyl salicylate to build up," explained Klessig. "It then flows through the phloem (or food-conducting "tubes") to the uninfected tissue, where SABP2 converts it back into active SA, which can now turn on the plant's defenses." Klessig said that it is unclear why plants send this hormone to uninfected tissue in an inactive form, which then must be activated by removal of the methyl group. "This research also provides insight into how a hormone like SA can actively regulate its own structure -- and thereby determine its own activity -- by controlling the responsible enzyme," noted Park, the lead author of the paper. Cornell University News Service |
|||||||||||||||||||||
| Related Immune Response Current Events and Immune Response News Articles New Notre Dame study provides insights into the molecular basis of tumor cell behavior A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa. Study reveals a 'missing link' in immune response to disease The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery. Initial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. Progress made on group B streptococcus vaccine Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Scientists use world's fastest supercomputer to create the largest HIV evolutionary tree Supporting Los Alamos National Laboratory's role in the international Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, researchers are using the Roadrunner supercomputer to analyze vast quantities of genetic sequences from HIV infected people in the hope of zeroing in on possible vaccine target areas. Study shows how carbon nanotubes can affect lining of the lungs Carbon nanotubes are being considered for use in everything from sports equipment to medical applications, but a great deal remains unknown about whether these materials cause respiratory or other health problems. More Immune Response Current Events and Immune Response News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||